We investigated the activity of roxithromycin (RU 965) and gamma interferon alone and in combination in a murine model of toxoplasmic encephalitis. Roxithromycin at a dosage of 35 or 50 mg per mouse per day decreased mortality. Gamma interferon alone significantly prolonged time to death. When combined, the two agents were remarkably synergistic.
pended to the desired concentration in Hanks balanced salt solution (GIBCO Laboratories, Grand Island, N.Y.) containing 100 U of penicillin per ml and 100 pug of streptomycin per ml. Unless stated otherwise, the concentration of parasites was 3.3 x 106/ml. Viability of the organisms was greater than 95% as determined by trypan blue exclusion.
Injections were delivered into the right frontal lobe of the brain with the use of a stereotactic unit as described previously (Hofflin et al., in press). After anesthesia with methoxyfluorane and placement in the stereotactic unit, the skull was penetrated with a 0.5-in. (ca. 1.3-cm), shortbeveled 23-gauge needle. A 30-gauge needle was passed through the 23-gauge needle into the brain to a measured depth of 3 mm, and a 3-pul inoculum (104 organisms) of the tachyzoite suspension was injected with a 50-pl glass syringe. The 30-gauge needle was checked for patency after each injection, and mice were euthanized if needle blockage had occurred.
Roxithromycin (Hoechst-Roussel Pharmaceuticals, Inc., Somerville, N.J.) was thoroughly mixed into powdered mouse feed (Simonsen Laboratories) with a food mixer for a minimum of 6 h. The amount of antibiotic added to the feed was determined based on the observation that mice of this weight consume approximately 4 g of feed per day (1). The mice were given ad libitum access to the feed in containers covered with grids which minimize spillage so that an estimate of ingested feed could be made.
Recombinant murine gamma interferon (Genentech, South San Francisco, Calif.) was diluted in phosphatebuffered saline with 10% fetal bovine serum (PBS), and 0.2 ml was injected intravenously via the tail vein. Control mice received PBS alone. Injections were administered every other day for three doses beginning 6 h after intracerebral infection.
The brains of mice that survived 10 weeks after infection were each triturated in a mortar and mixed with 1 ml of normal saline. The suspension was drawn up and expressed through a 22-gauge needle four times. A 50-pul sample of the resulting suspension was placed on a microscope slide under a coverslip (20 by 50 mm), the entire slide was scanned, and Toxoplasma cysts were counted. Because earlier studies from our laboratory (10) showed insignificant differences in the numbers of cysts in multiple samples from an individual suspension, only single preparations were counted. All statistical analyses were performed by the chi-square method. Roxithromycin (10 mg per mouse per day) that was administered 2 days before infection had no effect on the 100% mortality rate or the median time to death of 10.5 days. When the experiment was repeated with 50 mg of roxithromycin per mouse per day (Fig. la) In a preliminary experiment, gamma interferon (106 U) significantly (P = 0.006) decreased mortality on day 8 and prolonged time to death (median, 10 versus 8 days) but did not alter mortality (100%) at 1 month. When gamma interferon (5 x 104 U) and roxithromycin (35 mg per mouse per day) were both administered 2 h before infection with T. gondii, there was a remarkable synergistic effect (Fig. 2a) .
Survival was increased from 0 to 40% (P = 0.02). When the experiment was repeated with a lower dosage of roxithromycin, the results were even more impressive (P = 0.002; Fig. 2b) .
We extended the earlier finding of a protective effect of roxithromycin in T. gondii-infected mice to include protection in a model of murine toxoplasmic encephalitis. This series of experiments did not address the issue of whether the death of experimental mice resulted from infection of the brain or other vital organs; however, the reduced numbers of Toxoplasma. cysts in the brains of roxithromycin-treated mice suggest that the antibiotic did exert an effect in the brain parenchyma. There are no data about the penetration of the blood-brain barrier by roxithromnycin (W. Novick, personal communication), but it is anticipated that it will be similar to that by erythromycin which,. in the presence of inflamed meninges, achieves levels in the cerebrospinal fluid of 5 to 10% of levels in serum (11) . We previously reported that the histopathological changes in the brains of mice after intracerebral inoculation with T. gondii resemble those reported in patients with acquired immune deficiency syndrome and toxoplasmic encephalitis (Hofflin et al., in press). These changes, which include inflammation and marked tissue destruction, suggest the possibility that damage to the blood-brain barrier allows roxithromycin to reach effective levels in the involved areas of the brains of such patients. The ability of gamma interferon to prolong survival in murine toxoplasmosis (4) was confirmed in our studies. The mechanism of protection may be complex. An in vitro inhibitory effect of interferon on Toxoplasma replication has been described by several workers (6, 8, 12) . In addition to this inhibitory activity, interferon can activate macrophages to inhibit or kill Toxoplasma spp. (4, 5) . Whether otle or both of these activities of interferon contributed to the striking synergistic effect observed with roxithromycin remains to be defined. We consider it likely that the synergy which we observed will occur when gamma interferon is combined with other antibiotics which have activity against T. gondii in vivo.
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